Drug Type Monoclonal antibody |
Synonyms NIVOLUMAB/ELATLIMAB-RMBW, Relatlimab/Nivolumab, BMS-936558/BMS-986016 + [2] |
Target |
Mechanism LAG3 inhibitors(Lymphocyte activation gene 3 protein inhibitors), PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (18 Mar 2022), |
RegulationPriority Review (US), Fast Track (US), Orphan Drug (US), Paediatric investigation plan (EU) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Metastatic melanoma | EU | 15 Sep 2022 | |
Metastatic melanoma | IS | 15 Sep 2022 | |
Metastatic melanoma | LI | 15 Sep 2022 | |
Metastatic melanoma | NO | 15 Sep 2022 | |
Unresectable Melanoma | EU | 15 Sep 2022 | |
Unresectable Melanoma | IS | 15 Sep 2022 | |
Unresectable Melanoma | LI | 15 Sep 2022 | |
Unresectable Melanoma | NO | 15 Sep 2022 | |
Melanoma | US | 18 Mar 2022 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Colorectal Carcinoma | Phase 3 | US | 28 Apr 2022 | |
Metastatic Colorectal Carcinoma | Phase 3 | JP | 28 Apr 2022 | |
Metastatic Colorectal Carcinoma | Phase 3 | AR | 28 Apr 2022 | |
Metastatic Colorectal Carcinoma | Phase 3 | AU | 28 Apr 2022 | |
Metastatic Colorectal Carcinoma | Phase 3 | AT | 28 Apr 2022 | |
Metastatic Colorectal Carcinoma | Phase 3 | BE | 28 Apr 2022 | |
Metastatic Colorectal Carcinoma | Phase 3 | CA | 28 Apr 2022 | |
Metastatic Colorectal Carcinoma | Phase 3 | CL | 28 Apr 2022 | |
Metastatic Colorectal Carcinoma | Phase 3 | CZ | 28 Apr 2022 | |
Metastatic Colorectal Carcinoma | Phase 3 | FR | 28 Apr 2022 |
Phase 2/3 | - | 714 | ndrzrcjfrf(kcqreorzab) = sjrsmzgxkd usnzridfqj (llenvenjoq ) View more | Positive | 10 Sep 2022 | ||
ndrzrcjfrf(kcqreorzab) = khewiqsnka usnzridfqj (llenvenjoq ) View more |